Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

Sponsor
Hoffmann-La Roche
Study ID
NCT02608112
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Methotrexate — DRUG
    Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
  • Tocilizumab — DRUG
    Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.

Study Details

This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to severe rheumatoid arthritis (RA).

Key Dates

Start date
Dec 31, 2015
Status verified
Feb 2020
Primary completion
Jul 26, 2018
Completion
Jul 26, 2018

Study Design

Enrollment
291 participants (estimated)

Arms

  • Arm: Participants with Moderate to Severe RA
    Participants with moderate or severe RA, naïve to TCZ treatment (IV or SC), and who have no contra-indication to TCZ SC therapy as per the local label are included.

Primary Outcome Measure

Percentage of Participants Who Were on TCZ SC for a Period of 12 Months [ Time Frame: Up to 12 Months ]

Related Studies